News

Educational Webinar: 9 March 2021 | Myoclonus dystonia (paediatric focus)

The European Reference Networks for Rare Neurological Diseases (ERN-RND) and Neuromuscular Diseases (ERN EuroNMD) together with the European Academy of Neurology (EAN) has organised an educational webinar on Myoclonus dystonia focused on paediatric. Myoclonus dystonia can begin in the first 20 years of life and affects neck, arms and trunk but it can also occur

February 22nd, 2021|

PUBLIC CONSULTATION: BLOOD, TISSUES, AND CELLS (BTC) FOR MEDICAL TREATMENTS & THERAPIES – REVISED EU RULES

The EU is revising the rules on scientific and technological developments regarding blood, tissues, and cells for medical treatments and therapies. On 21 January 2021, the Commission launched a public consultation to collect the views of all interested citizens and organisations that will remain open until 15 April 2021. The consultation concerns an initiative for

February 22nd, 2021|

PAEDIATRIC MEDICINES IN EUROPE: IS IT TIME FOR REFORM?

On February the 2nd 2021, the Frontiers in Medicine journal (Impact factor 3.9) published the article named ‘Paediatric Medicines in Europe: The Paediatric Regulation—Is it Time for Reform?’ The article, written by regulatory experts from the TEDDY Network, is aimed at verifying if the European Paediatric Regulation (EC) N° 1901/2006 satisfies the paediatric therapeutic needs

February 22nd, 2021|

Enpr-EMA ASSENT/CONSENT GUIDANCE

Consent requirements are not harmonised in Europe and vary according to national laws and regulations. These discrepancies can present challenges for paediatric clinical trials, especially as many are conducted as multinational trials. The Enpr-EMA working group on ethics, of which Viviana Giannuzzi and Cristina Manfredi are members representing the TEDDY Network, has published the “Assent

February 22nd, 2021|

TEDDY educational activities within EJPRD

Within the European Joint Programme on Rare Diseases (EJPRD), Pillar 3 WP15, TEDDY is responsible of the preparation for the educational materials and training activities for the paediatric patients. Education of young people is essential to incorporate them as advisors along the drug development process. A patient-centred approach can improve the capacity of collaboration with

February 22nd, 2021|

COVID-19: WHAT ABOUT CHILDREN AND YOUNG PEOPLE?

In full COVID-19 emergency, most scientific studies have focused their research on adult patients. New drugs, vaccines and transmissibility factors were only analysed in the case of adult patients and children and adolescents were given little consideration. As it is appropriately indicated in the article: It’s Time to Put Children and Young People First During

February 22nd, 2021|

Paediatric formulation gap survey

The WHO has initiated a comprehensive gap analysis of the most needed medicines for children in view of its upcoming review of the Essential Medicines List for children (EMLc). To support the WHO review of the Essential Medicines List for children, the Global Accelerator for Paediatric formulations (GAP-f), a WHO-led network focused on achieving Universal

February 22nd, 2021|

TEDDY NETWORK IS FRIEND OF RARE DISEASE DAY

In occasion of the fourteenth edition of the Rare Disease Day, promoted by EURORDIS, that will be held on February 28th, TEDDY Network has become a friend and is supporting this great initiative again this year! The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their

February 4th, 2021|

EJP RD INFORMATION WEBINAR FOR THE JTC2021

The EJP RD is organising an online webinar to provide the potential applicants to the Joint Transnational Call 2021 on “Social Sciences and Humanities Research to Improve Health Care Implementation and Everyday Life of People Living with a Rare Disease” details on the call's objectives, topics and administrative rules. The webinar will take place on

January 27th, 2021|

TEDDY comments to the EC public consultation on the revision of the EU legislation on medicines for children and rare diseases

On 6 January 2021, The European Commission has closed the Public Consultation for the inception impact assessment on the revision of the Orphan and Paediatric Regulation. The aim of this initiative was to explore the need for adequate measures to overcome the lack of medicines in the paediatric field. TEDDY Network participated in the EC Consultation

January 26th, 2021|